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R	=	substituent	group		 -	 H	 				methcathinone	
	 	 	 	 	 	 -	 F	 										flephedrone	
	 	 	 	 	 	 -	 Cl	 										clephedrone	
	 	 	 	 	 	 -	 Br	 								brophedrone	
	 	 	 	 	 	 -	 CH3	 									mephedrone	





























































































DRUG	 Imax	 Imax	error	 EC50	 EC50	error	
Brephedrone	 103.37	 0.57	 0.52	 0.01	
Mephedrone	 112.12	 4.34	 1.2	 0.128	
Clephedrone	 108.46	 8.39	 1.29	 0.33	
Flephedrone	 84.55	 7.48	 4.67	 1.36	
Methedrone	 203.39	 20.15	 5.56	 1.33	



















4.4	Correlational	Comparisons				 The	EC50	values	calculated	from	concentration-effect	curves	in	oocytes	for	each	drug	compound	were	first	correlated	with	the	nanomolar	in-vitro	release	EC50	values	from	Bonano	et	al.,	2014	and	Baumann	et	al.,	2012.		The	results	were	statistically	significant,	with	the	p	value	equaling	0.039	and	the	r	value	equaling	0.83,	indicating	a	predictive	relationship	between	the	two.		The	correlational	results	can	be	seen	in	Figure	4.15.	Next,	the	EC50	oocyte	values	and	their	respective	cubic	angstrom	volume	amounts	were	compared.		The	resulting	correlation	gave	a	weak	correlation	between	the	two	(p	=	0.0026,	r	=	-0.56),	mainly	due	to	the	outlier	methedrone	(4-OCH3	MCAT).		When	methedrone	was	excluded,	it	resulted	in	a	strong	correlation	between	the	EC50	values	and	volume	(p	=	0.0005,	r	=	-0.992).		The	results	with	the	outlier	can	be	seen	in	Figure	4.16	and	the	correlation	without	methedrone	are	seen	in	Figure	4.17.		 After	the	previous	correlations	suggested	that	methedrone	is	an	outlier,	other	correlations	were	performed	to	search	for	a	possible	explanation.		First,	the	EC50	values	were	correlated	with	Taft’s	Steric	Parameter	(listed	in	Table	4.14),	or	a	measure	of	overall	steric	bulk,	different	from	the	cubic	angstrom	values	of	volume	used	previously.		This	resulted	in	a	strong	and	statistically	significant	correlation	(p	=	0.003,	r	=	0.95)	and	can	be	seen	in	Figure	4.18.				 Next,	the	EC50	values	from	oocytes	were	correlated	with	the	corresponding	values	for	each	4-para	substitution’s	electron	withdrawing	capacity.		These	values	can	be	found	in	Table	4.14.		The	results	from	this	correlation	were	statistically	insignificant	(p	=	0.377,	r	=	-0.445)	and	can	be	seen	in	Figure	4.19.			
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	 Values	of	lipophilicity	for	each	compound	were	correlated	with	their	EC50	values	obtained	from	oocyte	concentration-effect	curves.		The	results	were	statistically	significant	with	p	=	0.004	and	r	=	-0.933.		The	lipophilicity	values	for	each	compound	can	be	found	in	Table	4.14	and	the	correlation	results	can	be	seen	in	Figure	4.20.		 The	measurements	of	volume	do	not	correlate	strongly	with	the	corresponding	Taft’s	E	values,	as	can	be	seen	in	Figure	4.21.		The	correlation	resulted	in	r	=	-0.65	and	p	=	0.16.		Once	again,	methedrone	(4-OCH3	MCAT)	appeared	to	be	an	outlier	so	the	correlation	was	performed	again	without	methedrone.		The	results	were	statistically	significant	(r	=							-0.97,	p	=	0.005)	and	can	be	seen	in	Figure	4.21	as	well.		 Unlike	the	EC50	values	obtained	from	oocyte	concentration	curves,	the	EC50	values	from	Baumann	et	al.	(2012)	correlate	strongly	with	Taft’s	E	and	measures	of	volume.		The	results	for	EC50	values	in	synaptosomes	correlated	with	Taft’s	E	are	shown	in	Figure	4.22	(r	=	0.88,	p	=	0.02)	and	the	results	for	EC50	values	in	synaptosomes	correlated	with	volume	can	be	found	in	Figure	4.23	(r	=	-0.92,	p	=	0.008).		All	the	values	used	can	be	seen	in	Table	4.14.		 Lastly,	the	EC50	values	from	oocyte	concentration	curves	were	correlated	with	both	substituent	length	and	maximum	width	of	the	substituent.		Both	returned	statistically	insignificant	correlations	when	methedrone	(4-OCH3	MCAT)	was	included.		EC50	values	correlated	with	length	are	shown	in	Figure	4.24	(r	=	-0.61,	p	=	0.19)	and	EC50	values	correlated	with	maximum	width	are	shown	in	Figure	4.26	(r	=	-0.32,	p	=	0.54).		When	methedrone	was	excluded,	both	returned	strong	and	statistically	significant	correlations.		Figure	4.25	displays	the	correlation	between	EC50	values	and	substituent	length,	without	methdrone	(r	=	-0.96,	p	=	0.01).		The	correlation	between	EC50	values	and	substituent	
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maximum	width,	excluding	methedrone,	can	be	seen	in	Figure	4.27	(r	=	-0.95,	p	=	0.01).		The	values	for	substituent	length	and	width	were	borrowed	from	the	Sakloth	et	al.	(2014)	paper	and	can	be	found	below	in	Table	4.14.						
			
	
	
Table	4.14:		Values	used	in	each	correlational	comparison.		The	EC50	values	in	oocytes	are	measured	in	micromolar	amounts.		EC50	values	in	synaptosomes	are	nanomolar	(Bonano	et	
al.,	2014,	Baumann	et	al.,	2012)	and	volume	is	cubic	angstroms	(Sakloth,	et	al.	2015).		Taft’s	values	are	a	measure	of	functional	steric	bulk,	EWC	is	short	for	‘electron-withdrawing	capacity’,	and	the	lipophilicity	of	each	compound	is	also	shown..	(Sakloth,	et	al.	2015).		Physochemical	parameters	(Taft’s,	EWC,	Lipophilicity)	borrowed	from	Wolff,	1980.		Finally,	the	length	of	substituent	(Å),	and	maximum	width	of	substituent	(Å)	for	each	compound	are	also	listed	(Sakloth,	et	al.	2015).		
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Figure	4.15:	LogEC50	values	from	concentration-effect	curves	in	oocytes	correlated	with	the	logEC50	values	from	Bonano	et	al.,	2014	and	Baumann	et	al.,	2012,	found	in	Table	4.14.					
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Figure	4.16:	Correlational	analysis	of	EC50	values	obtained	from	oocyte	concentration-effect	curves	including	methedrone	(4-OCH3	MCAT).		Results	are	statistically	significant	but	with	a	very	weak	correlation.		Volume	values	for	each	compound	can	be	found	in	Table	4.14.					
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Figure	4.17:	Correlational	analysis	of	EC50	values	obtained	from	oocyte	concentration-effect	curves	and	respective	values	of	volume	for	each	compound,	excluding	methedrone	(4-OCH3	MCAT)	shown	here	in	red.		Results	are	statistically	significant,	with	a	very	strong	correlation	suggesting	that	methedrone	is	an	outlier.		Volume	values	for	each	compound	can	be	found	in	Table	4.14.						
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Figure	4.18:	Correlational	analysis	of	EC50	values	obtained	from	oocyte	concentration-effect	curves	and	Taft’s	Steric	E	values,	or	a	measure	functional	steric	bulk.		Taft’s	values	for	each	compound	can	be	found	in	Table	4.14.						
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Figure	4.19:	Correlational	analysis	of	EC50	values	obtained	from	oocyte	concentration-effect	curves	and	Electron-Withdrawing	Capacity	(EWC)	values.		EWC	values	for	each	compound	can	be	found	in	Table	4.14.		This	correlation	is	statistically	insignificant,	but	if	we	exclude	4-CH3	MCAT	and	4-OCH3	MCAT	then	the	results	are	statistically	significant	(r	=	-0.96,	p	=	0.04).				
	65	
			
Figure	4.20:	Correlational	analysis	of	EC50	values	obtained	from	oocyte	concentration-effect	curves	and	lipophilicity	values.		Lipophilicity	values	for	each	compound	can	be	found	in	Table	4.14.				
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Figure	4.21:	Correlation	between	Taft’s	Steric	E	and	the	volume	of	each	methcathinone	analog.		All	values	can	be	found	in	Table	4.14.		The	correlation	between	Taft’s	and	Volume	is	weak	and	statistically	insignificant,	r	=	=0.65	and	p	=	-0.16.		When	methedrone	(4-OCH3	MCAT)	is	excluded,	r	=	-0.97	and	p	=	0.005,	suggesting	that	particular	point	is	an	outlier.					
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Figure	4.22:	Correlational	analysis	between	all	six	EC50	values	in	synaptosomes	(Baumann	
et	al.,	2012)	and	Taft’s	Steric	E	(Bonano	et	al.,	2014).		The	result	is	statistically	significant,	with	an	r	value	of	0.88	and	a	p	value	of	0.02.		All	values	can	be	found	in	Table	4.14.								
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Figure	4.23:	Correlational	analysis	between	all	six	EC50	values	in	synaptosomes	(Baumann	
et	al.,	2012)	and	the	volume	of	each	corresponding	compound.		The	correlation	is	statistically	significant,	r	=	-0.92	and	p	=	0.008.		All	the	values	can	be	found	in	Table	4.14.								
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Figure	4.24:	The	EC50	values	from	concentration	curves	in	oocytes	correlated	with	the	length	of	each	substituent,	in	angstroms.		The	substituent	length	values	can	be	found,	along	with	the	EC50	values,	in	Table	4.14.		The	correlation	gave	a	statistically	insignificant	result,	r	=	-0.61	and	p	=	0.19.									
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Figure	4.25:		Excluding	methedrone	(4-OCH3	MCAT),	the	EC50	values	from	concentration	curves	in	oocytes	correlated	with	the	length	of	each	substituent.		The	substituent	length	values	can	be	found,	along	with	the	EC50	values,	in	Table	4.14.		Unlike	the	previous	correlation	(with	methedrone	included),	the	results	were	statistically	significant	–	r	=	-0.96	and	p	=	0.01.						
	71	
					
Figure	4.26:	The	EC50	values	from	concentration	curves	in	oocytes	correlated	with	each	substituent’s	width,	in	angstroms.		The	results	are	statistically	insignificant,	r	=	-0.32	and		p	=	0.54.		All	values	can	be	found	in	Table	4.14.									
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Figure	4.27:	Correlational	statistics	between	the	EC50	values	from	concentration	curves	in	oocytes	and	the	width	of	each	substituent,	excluding	methedrone	(shown	in	red).		The	results	of	this	correlation	are	statistically	significant	after	excluding	the	methedrone	outlier	point	(r	=	-0.95,	p	=	0.01).									
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Table	4.28	:	A	summary	of	all	correlational	analyses	performed.		Results	are	listed	here	including	the	exact	R	and	P	values.		Visual	representations	of	each	correlation	can	be	found	in	Figures	4.15	–	4.27.					
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Discussion	
	
			 Two	different	variations	of	the	Hill	equation	were	used	to	calculate	maximum	currents	and	EC50	values	for	the	six	4-para	substituted	methcathinone	compounds.		The	‘Hill’	equation	was	fitted	to	flephedrone	(4-F	MCAT),	brephedrone	(4-Br	MCAT),	and	clephedrone	while	the	‘Hill1’	equation	was	used	for	methcathinone	(MCAT),	methedrone	(4-OCH3	MCAT),	and	mephedrone	(4-CH3	MCAT).		The	Hill1	equation	includes	an	offset	and	was	used	when	the	lowest	concentration	of	each	compound	(0.1	micromolar)	recorded	was	significantly	greater	than	zero.		Flephedrone,	brephedrone,	and	clephedrone	either	elicited	no	response	at	the	0.1	micromolar	concentration,	or	were	trending	toward	zero	and	the	Hill1	offset	was	not	needed.		Methcathinone	required	more	data	points	for	a	proper	Hill	equation	fit	due	to	its	high	EC50	value.		Recordings	were	taken	at	0.1,	0.5,	1.0.	5.0,	10.0,	30.0,	50.0,	and	100.0µM-drug	concentrations	for	methcathinone.				 Five	of	the	six	compounds	were	found	to	have	reasonably	similar	maximum	currents	(between	84-113	nano-amps),	while	methedrone	(4-OCH3	MCAT)	had	a	maximum	current	of	203.39	nano-amps.		The	much	larger	maximum	current	suggests	that	methedrone	is	much	more	efficacious	at	hSERT	than	the	other	compounds.		In	other	words,	methedrone	is	much	better	at	opening	the	transporter	and	allowing	current	to	flow	thru	regardless	of	potency	at	the	transporter.		The	vast	difference	in	maximal	current	adjusts	methedrone’s	EC50	to	the	right	on	the	graph	–	or	makes	it	larger	than	expected.		Baumann	
et	al.	(2012)	and	Bonano	et	al.	(2014)	simply	looked	at	total	release	of	serotonin	in	
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synaptosomes	caused	by	each	compound.		Methcathinone	might	have	caused	total	release	much	quicker	than	the	other	compounds,	but	their	experimental	set	up	did	not	take	into	account	the	differences	in	time	of	release	and	efficacy	of	the	compounds.		This	could	possibly	explain	methcathinone’s	lack	of	correlation	between	oocyte	and	synaptosome	data	(seen	in	Figure	4.15).		Methcathinone’s	degree	of	efficacy	at	the	serotonin	transporter	could	also	have	other	effects,	if	repeatable	in	vivo.		Is	it	possible	that	methcathinone	might	activate	other	transporters	or	channels	as	well	due	to	its	high	degree	of	efficacy.		For	instance,	the	amount	of	current	caused	my	methedrone	acting	on	the	serotonin	transporter	could	be	enough	to	activate	surrounding	calcium	channels.		Methedrone’s	effects	at	other	related	transporters	would	be	an	interesting	continuation	of	this	project,	due	to	its	high	efficacy	and	possible	potential	for	toxicity.		 Each	of	the	six	compounds	considered	in	this	thesis	produced	concentration-dependent	effects	at	hSERT.		Brephedrone	was	shown	to	be	the	most	potent	compound	eliciting	effects	on	the	serotonin	transporter	followed	by	(in	order	of	potency)	mephedrone,	clephedrone,	flephedrone,	methedrone,	and	methcathinone.		The	Bonano	et	
al.	(2015)	paper	suggested	that	the	larger	the	Taft’s	Steric	E	(ES	value),	the	more	potent	a	compound	would	be	for	DAT	instead	of	SERT.		In	other	words,	the	ES	value	is	inversely	related	to	the	amount	of	steric	bulk,	and	the	lower	the	ES	value,	the	more	potent	the	compound	should	be	at	hSERT.		The	SERT	EC50	values	in	oocytes	calculated	from	the	data	acquired	for	this	thesis	(Table	4.10)	somewhat	agree	with	the	Bonano	et	al.	paper.		Methcathinone	has	the	smallest	functional	steric	bulk	of	the	six	compounds	(ES	=	1.24),	should	be	the	most	selective	at	DAT,	and	clearly	is	the	least	potent	at	SERT	with	a	EC50	of	15.73.		Methedrone	(4-OCH3	MCAT)	appears	to	be	the	next	least	potent	at	SERT	in	our	data	
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(EC50	=	5.56)	and	this	almost	agrees	with	the	ES	value	(0.69)	where	methedrone	is	the	third	highest.		Bonano	et	al.	found	methedrone	to	be	an	outlier,	having	the	most	selectivity	at	SERT.		The	data	here	does	not	agree	with	Bonano	et	al.’s	calculations	of	methedrone,	and	comes	closer	to	following	the	predictions	made	from	ES	values.		Based	on	these	ES	value	predictions,	flephedrone	(4-F	MCAT,	ES	=	0.78)	should	be	the	second	least	potent	at	SERT	behind	methcathinone,	but	our	data	suggest	that	flephedrone	(EC50	=	4.67,)	is	third	least	potent.		Clephedrone	(4-Cl	MCAT,	ES	=	0.27)	has	the	next	lowest	ES	value,	Bonano	et	al.	calculated	it	to	be	the	next	highest	in	SERT	selectivity,	and	our	data	(EC50	value	of	1.29	[+/-0.33])	agree.		Mephedrone	(4-CH3	MCAT,	ES	=	0)	was	found	to	be	the	second	most	potent	compound	at	SERT	in	both	data	sets	(EC50	=	1.20).		Bonano	et	al.	found	brephedrone	(4-Br	MCAT)	to	be	the	most	potent	compound	at	SERT,	while	having	the	second	lowest	ES	value	(0.08).		Our	data	from	oocyte	concentration	curves	agrees	with	the	Bonano	et	al.	paper	in	that	brephedrone	(EC50	=	0.52)	is	the	most	potent	compound	at	the	hSERT	transporter.		In	summary,	the	data	collected	for	this	thesis	mostly	agrees	with	Bonano	et	al.	prediction	that	as	the	substituent’s	ES	value	gets	smaller	the	compound	becomes	more	SERT	selective.		 Correlational	statistical	experiments	were	employed	using	the	new	EC50	values	from	the	concentration-effect	curves	in	oocytes.		First,	the	new	EC50	values	from	oocytes	were	calculated	with	the	EC50	values	from	synaptosomes	in	Bonano	et	al.	(2014)	and	Baumann	et	
al.	(2012)	(all	values	can	be	found	in	Table	4.14).		This	resulted	in	a	significant	correlation	between	the	two	sets	of	EC50	values	(p	=	0.039,	r	=	0.83)	suggesting	that	the	concentration	effect	curve	for	each	compound	is	similar	in	both	xenopus	oocytes	and	synaptosomes,	and	can	be	seen	in	Figure	4.15.	
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	 Next,	a	correlational	analysis	was	performed	between	EC50	values	from	oocytes	and	a	measure	of	volume	for	each	4-para	substituted	compound.		These	values	of	volume	in	cubic	angstroms	were	borrowed	from	Sakloth,	et	al.	2015	and	can	also	be	found	in	Table	4.14.		The	correlation	between	volume	and	oocyte	EC50	values	is	very	weak	but	statistically	significant	with	a	p	value	of	0.0026	and	an	r	value	of	-0.56,	shown	in	Figure	4.16.		When	volume	and	EC50	values	are	plotted,	like	in	Figure	4.16,	it	is	obvious	that	one	point	is	an	outlier	compared	to	the	others.		That	data	point	is	methedrone	(4-OCH3	MCAT),	with	the	second	highest	EC50	value	of	5.56	micromoles	and	the	second	lowest	volume	of	153.78	cubic	angstroms.		Another	correlation	was	performed	without	methedrone’s	data	point	and	the	results	differed	drastically.		Without	methedrone,	p	=	0.0005	and	r	=	0.992,	and	can	be	seen	in	Figure	4.17.		The	stark	contrast	between	the	correlations	of	volume	and	EC50	values,	with	and	without	the	methedrone	data	point,	suggest	that	it	could	be	an	outlier.		A	correlation	between	volume	and	Taft’s	E	(Figure	4.21)	supports	this	theory	because	methedrone	appears	to	be	an	outlier	here	as	well.		In	order	to	explore	why	methedrone	might	be	acting	in	such	a	way,	the	EC50	values	were	next	correlated	with	the	three	parameters	from	Bonano	et	al.	(2014):	Taft’s	steric	parameter,	electron-withdrawing	capacity,	and	lipophilicity.		 Bonano	et	al.	previously	hypothesized	that	MCAT	analogues	with	para	substituents	would	demonstrate	selectivity	for	either	DAT	or	SERT,	depending	on	the	substituent	(Bonano	et	al.,	2015).		In	Bonano	et	al.’s	paper,	the	only	statistically	significant	correlation	was	found	between	selectivity	at	the	transporters	(or	EC50	value)	and	functional	steric	bulk.		To	quantify	steric	bulk,	Bonano	et	al.	used	Taft’s	steric	parameter	(ES)	which	is	calculated	based	on	both	steric	strain	and	steric	hindrance	of	each	compound,	as	well	as	inductive,	
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resonance,	and	field	influences	(Bonano	et	al.,	2015).		ES	values	are	indirectly	related	to	the	amount	of	functional	steric	bulk.		In	other	words,	the	higher	the	ES	value,	the	lower	the	functional	steric	bulk	of	the	substituent.		The	calculated	ES	values	can	be	found	in	Table	4.14.		A	correlation	between	the	ES	values	and	the	EC50	values	produced	an	r	value	of	0.96	and	a	p	value	of	0.003,	and	can	be	seen	in	Figure	4.18.		This	is	a	strong	correlational	r	value,	and	a	p	value	less	than	0.05,	indicating	a	statistically	significant	correlation.		It	is	interesting	that	the	EC50	values	in	oocytes	correlate	well	with	the	experimental	Taft’s	E	value	but	not	volume,	while	the	EC50	values	from	synaptosomes	correlate	with	both.		 The	cause	for	methedrone	(4-OCH3	MCAT)	being	an	outlier	in	the	EC50	versus	volume	plot	could	potentially	be	caused	by	electronic	factors	of	the	substituent	group.		To	explore	this	possibility,	a	correlation	was	performed	between	EC50	values	and	the	electron-withdrawing	capacity	of	each	4-para	substituent	compound.		Methedrone	possesses	the	lowest	electron-withdrawing	capacity	(EWC	=	-0.27)	and	all	the	electron-withdrawing	values	can	be	found	in	Table	4.14.		The	correlation	experiment	returned	a	weak	r	value	of					-0.445	and	a	high	p	value	of	0.377.		These	results,	shown	in	Figure	4.19,	suggest	that	electron-withdrawing	capacity	is	not	the	cause	of	methedrone’s	aberrant	placement	on	the	EC50	vs.	volume	plot	and	methedrone’s	strangely	weak	potency	at	the	serotonin	transporter.		 The	relationship	between	the	EC50	value	of	each	compound	and	lipophilicity	was	correlated	and	the	resulting	values,	r	=	-0.933	and	p	=	0.004,	propose	a	significant	statistical	relationship	between	the	lipophilcity	and	the	EC50	value	of	each	compound.		Figure	4.20	illustrates	the	correlation	and	suggests	that	the	liophilicity	of	each	4-para	substituted	methcathinone	compound	could	influence	the	respective	EC50	values.	
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	 The	EC50	values	obtained	by	Baumann	et	al.	(2012)	in	synaptosomes	correlate	strongly	with	both	Taft’s	E	(Figure	4.22,	r	=	0.88,	p	=	0.02)	and	volume	(Figure	4.23,	r	=	-0.92,	p	=	0.008).		The	EC50	values	from	oocytes	correlate	with	EC50	values	from	synaptosomes,	but	not	with	volume	and	Taft’s	E	signifying	a	difference	modulating	EC50	values	in	oocytes	that	does	not	exist	in	synaptosomes.		Oocyte	EC50	values	have	been	shown	to	correlate	well	with	values	of	substituent	length	and	width,	(Figures	4.25,	4.27)	similar	to	synaptosomes	when	excluding	methedrone.		Thus	the	discrepancies	in	EC50	values	between	synaptosomes	and	oocytes	could	be	caused	by	a	difference	in	expression,	protein	packaging,	or	modification	and	previous	experiments	have	shown	differing	EC50	values	in	
Xenopus	oocytes	when	compared	to	values	in	rat	syaptosomes	(Dowd	et	al.	1996).				 In	conclusion,	each	of	the	six	4-para	substituted	methcathinone	compounds	elicit	a	distinct	response	at	the	human	serotonin	transporter.		The	particular	substitution	made	at	the	4-position	on	the	benzyl	ring	influences	the	overall	potency	at	the	serotonin	transporter,	and	the	size	of	the	substitution	clearly	is	a	factor.		Substituent	volume	does	not	correlate	perfectly	though,	as	shown	by	the	outlier	methedrone	(4-OCH3	MCAT).		The	experimental	measurement	of	Taft’s	E,	which	takes	into	account	volume,	is	more	predictive	of	methcathinone	analog	efficicay	at	hSERT	and	the	data	suggest	other	factors	are	also	at	play.		Electron-withdrawing	capacity	was	shown	to	have	no	direct	influence	on	efficacy	and	EC50	values.		However,	the	lipophilicity	of	each	compound	provided	a	significant	correlation	to	the	EC50	values	found	from	oocyte	concentration-curves.		These	results	imply	the	general	rule:	the	larger	the	overall	volume	of	the	compound,	the	more	efficient	that	compound	will	be	at	the	serotonin	transporter	(compared	to	the	dopamine	transporter),	when	expressed	in	oocytes.		Outliers	are	possible	due	to	other	factors	including	lipophilicity	(and	excluding	
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steric	bulk	and	electron-withdrawing	capacity)	and	the	results	differ	in	other	assays	such	as	rat	synaptosome	experiments.		Such	dissimilarities	could	be	due	to	varying	membrane	lipid	and	protein	compositions	in	the	different	cell	types	or	any	number	of	pre	or	post-translational	modifications	to	the	transporter.		We	can	conclude	that	measurements	of	volume,	substituent	size,	and	steric	bulk	are	indirectly	related	to	methcathinone	analogue	potency	at	the	human	serotonin	transporter,	possibly	modulated	in	part	by	the	compound’s	lipophilicity	and	other	unknown	factors.					
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